ArticleFrontiers in immunology2025

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

Yutong Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.